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After BMMNCs, further advances in stem cell therapies included 
resident adult stem cells in the heart or lineage-specified cells to 
provide the therapeutic influence on the damaged tissue. Resident 
cardiac stem cells (CSCs, c-kit-positive cells) isolated from right 
atrial appendages were employed in the Phase I SCIPIO trial. One-
year follow-up outcome suggested beneficial effect of CSC therapy 
on LVEF and on infarct scar size in the treated patients [9]. The 
CADUCEUS autologous cardiosphere-based trial also confirmed 
therapeutic benefit on infarct scar dynamics [10], and the ALLSTAR 
and the RECONSTRUCT studies will further investigate the 
efficacy of allogenic cardiosphere-derived cells in AMI. An hybrid 
approach combining basic fibroblast growth factor (bFGF) together 
with autologous CSCs was utilized in the ALCADIA study. This 
combination approach of growth factors and stem cells prompted 
a new trend in regenerative cardiology. Within this context, an 
interesting alternative approach includes the methodology to 
guide adult multipotent stem cells towards cardiac lineage through 
manipulation of their culture environment as was assessed in the 
C-CURE trial [11] with Cardiopoietic human Mesenchymal Stem 
Cells (CP-hMSCs) (Table 1).
Discussion
These studies among others led to the observation that 
bioprocessing for regenerative cardiology is a new investigation field. 
More specifically, once the therapeutic cell source is determined 
for an intended clinical application, the safety and efficacy of the 
stem cell product has shown to be signiﬁcantly inﬂuenced by cell 
bioprocessing protocols. As a consequence, the development of 
robust production processes by optimizing culture variables is 
critical to manufacture biologics that retain desired regenerative 
properties while minimizing the potential risks [12,13]. There is not, 
as yet, consensus as to which will be the best cell for cardiac clinical 
applications and it is likely that we will not refer to one single cell 
type. As a direct result of the knowledge obtained through the first 
generation of clinical applications of stem cell-based therapeutics, 
a new focus has arisen on the development of reliable and robust 
culture procedures that will produce identical batches of cells for a 
given clinical application [14]. Further clarification of dosing and 
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Introduction
Preliminary studies based on stem cells were initially applied 
to the clinical setting of acute myocardial infarction (AMI) with 
the purpose of delivering a cardioprotective effect. The field 
has then rapidly expanded to embrace chronic heart failure as 
a cardiorestorative therapy [1]. For the easiness of collection as 
hematologic tissue, Bone Marrow (BM)-derived stem cells were 
utilized as the primary source of these applied therapies. Specifically, 
unselected Bone-Marrow Mononuclear Cells (BMMNCs) fuelled 
the first generation of clinical trials focused on cardiac regeneration. 
In the setting of AMI, the initial stem-cell based studies showed 
consistent although modest improvement in cardiac function and 
scar repair. In the largest European trial REPAIR-AMI, LVEF was 
significantly increased in the treated group compared to the patients 
receiving placebo [2]. The BOOST and the FINCELL trials further 
confirmed the significant improvement in LVEF by angiography 
in the stem cell treated groups [3,4]. By contrast, the latest HEBE 
trial completed in 2011, the Swiss-AMI trial and the ASTAMI trial 
reported similar or reduced effect of BMMNC therapy and the 
placebo [5-7]. Of note, in the HEBE trial, cells were processed for an 
undefined period of time and were delivered to patients in a heparin 
solution containing human serum albumin. Heparin as a reagent 
used in the harvesting of BM or in BMMNC delivery was later shown 
to disrupt the CXCR4–SDF-1 axis, thus reducing the chemotactic 
and functional capabilities of BMMNCs [8].
The different outcomes and the underlined variability in the 
methodologies employed in these early phase trials prompted the 
efforts for stem cell process development optimization. On the overall, 
cell manufacturing before implantation has been demonstrated to be 
crucial to provide the desired effect of cardiac regeneration.
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comprehensive characterization of stem cells is of utmost importance, 
as several trials have highlighted an inverse relationship between cell 
dose and clinical outcomes [15].
Stem and progenitor cells are plastic by definition and they 
constitute a live and functional reagent to be manufactured and 
administered to patients to exert a therapeutic effect. The successful 
process development of current laboratory-based protocols to the 
clinics requires the establishment of methods to achieve control, 
reproducibility, equivalence and safety of the stem cell product. 
Towards this objective, our group is focusing on the comprehensive 
approach of translating stem cell-based products to the clinics.
Cell culture variables are represented by the formulation of the 
media (basal media and their supplements), adhesion substrates, 
cell seeding density, together with the physiochemical environment 
(dissolved oxygen and carbon dioxide concentrations, temperature, 
pH, osmolality). Obviously, the defined nature of media optimized 
for isolation and expansion of stem cell therapy products facilitates 
the development of robust, clinically acceptable cells. Furthermore, 
in order to culture cells long-term the defined basal medium must be 
supplemented with several factors. Serum, of animal or human origin, 
is the most widely used among them. In particular, the development 
of cultures free of Fetal Bovine Serum (FBS) is warmly recommended 
from the ethical and scientific point of view. FBS composition 
is complex, its batch-to-batch variation, and the likelihood of 
contamination causes phenotypical differences in cell cultures and 
therefore variations in the derived cell therapy products [16,17]. To 
efficiently translate cell culture products to the clinics, cells should 
possibly be seeded in serum-free media just after isolation from 
the tissue of origin as a primary culture and then, according to the 
different protocols, expanded in the same serum-free culture medium 
or further supplemented with specific components, normally for a 
limited number of passages (on the average ≤ P5) to limit the risk of 
senescent or transformed phenotype. In order to develop serum-free 
cultures, cell adhesion is supported by the use of defined substrates. 
Well-defined recombinant substrates which are widely used such as 
Vitronectin or Laminin might be used to sustain cell attachment in 
serum-free conditions [18]. However, another valuable approach 
is represented by more specific animal component-free adhesion 
substrates which mimic the cardiac extracellular matrix, such as 
Fibronectin or Hyaluronic acid. Besides, given that each cell type has 
its own requirements for ex vivo expansion, further optimization of 
media formulation with defined specific growth factors is achieved to 
increase cell proliferation and activate or maintain specific cellular 
functions, for example their stemness profile [19]. Most growth 
factors are highly cell type speciﬁc. IGF-1 or Hepatocyte Growth 
Factor (HGF) have been described to exert a favorable effect on 
human Cardiac Stem Cells rejuvenation and mobilization in the 
damaged or senescent heart [20,21]. Other growth factors are known 
to be more pleiotropic and therefore can provide positive effects on 
several different cell types such as Fibroblast Growth Factor-2 or Stem 
Cell Factor (SCF). In general, a combination of animal component-
Table 1: First generation stem cell-based studies in ischemic heart disease
Study name Study ID, PI Year Stem Cell Type Cell manipulation Cell Number and route of 
administration
Effect on Ejection 
Fraction (EF)
Reinfusion of Enriched 
Progenitor Cells And Infarct 
Remodeling in Acute 
Myocardial Infarction
REPAIR-AMI
Schachinger V. et 
al. [2]
2006 BMMNCs Density gradient (Ficoll) 
centrifugation
1.98 × 108, intracoronary injection 
in X-VIVO™ 10 medium and 20% 
autologous serum
Positive by LV 
angiography
Bone-marrow-derived cell 
transfer after ST-elevation 
myocardial infarction
BOOST
Woller K. C. et al. [2]
2004 BMMNCs Density gradient (Ficoll) 
centrifugation
2.4 × 109, intracoronary injection 
(4 or five injections in heparinized 
saline)
Positive by MRI
Effects of intracoronary 
injection of mononuclear 
bone marrow cells on left 
ventricular function.
FINCELL 
Huikuri, H. V. et al. [3]
2008 BMMNCs Density gradient (Ficoll) 
centrifugation
3.6 × 109, intracoronary injection 
in unspecified medium and 50% 
autologous serum
Positive by 
echocardiography
Autologous Stem Cell 
Transplantation in Acute 
Myocardial Infarction
ASTAMI
Lunde K. et al. [6]
2006 BMMNCs Density gradient (Ficoll) 
centrifugation
6.8 × 107, intracoronary injection 
in heparin-treated plasma
No change by CT 
(SPECT)
Intracoronary infusion 
of mononuclear cells 
from bone marrow or 
peripheral blood compared 
with standard therapy 
in patients after acute 
myocardial infarction 
treated by primary PCI
HEBE 
Hirsch A. et al. [5]
2011 BMMNCs Density gradient 
(Lymphoprep) 
centrifugation
2.96 × 108, intracoronary injection 
in sodium heparin and 4% Human 
Serum Albumin (HSA)
No change by MRI
SWiss multicenter 
Intracoronary Stem cells 
Study in Acute Myocardial 
Infarction
SWISS-AMI, Sürder D. 
et al. [7]
2010 BMMNCs Density gradient (Ficoll) 
centrifugation 
≥ 5 × 107, intracoronary injection 
In 10 ml of X-VIVO 10
with 20% of
autologous serum
No change by 
Cardiac magnetic 
resonance (CMR) 
Cardiac Stem Cells in 
patients with Ischaemic 
cardiomyopathy 
SCIPIO
Bolli R. et al. [8]
2011 c-kit-positive 
resident Cardiac 
Stem Cells
Cell culture and Magnetic 
sorting (MACS)
0.5 × 106 to 1 × 106, intracoronary 
injection in PlasmaLyte A
Positive by 
Echocardiography
Intracoronary 
cardiosphere-derived cells 
for heart regeneration after 
myocardial infarction
CADUCEUS Makkar 
R.R. et al. [10]
2012 Cardiosphere-
derived cells
Cell culture of primary 
explant to obtain 3D 
cardiospheres.
1.3 × 107 to 2.5 × 107, 
intracoronary injection in in normal 
saline, heparin (100 U/ml) and 
nitroglycerin (50 µg/ml)
No change by cMRI.
(Further 
advancement in 
ALLSTAR and 
RECONSTRUCT 
trials)
Cardiopoietic stem Cell 
therapy in heart failURE
C-CURE,
Bartunek, J. et al. [11]
2013 Cardiopoietic 
hMSCs 
Cell culture guidance and 
lineage specification
6.0 × 108 to 1.2 × 109, NOGA 
guided injections of 5% HAS in 
lactated Ringer’s solution.
Positive by 
Echocardiography.
(Further 
advancement in 
CHART-1 and 
CHART-2 trials)
Abbreviations: MI = Myocardial Infarction; AMI = Acute Myocardial Infarction; BMMNCs= Bone Marrow Mononuclear Cells; SPECT = Single-Photon Emission 
Computed Tomography; LV= Left ventricular; MRI = Magnetic Resonance Imaging; PCI = Percutaneous Coronary Intervention; hMSCs = human Mesenchymal Stem 
Cells; HSA = Human Serum Albumin.
Bardelli and Moccetti. Int J Stem Cell Res Ther 2016, 3:1 • Page 3 of 3 •ISSN: 2469-570X
free recombinant widely distributed and more specific growth factors 
might be taken into consideration for the development of a stem 
cell therapy product. In addition, to fine tune the design of a specific 
cell therapy product, the supplementation of lipids, antioxidants 
and/or speciﬁc vitamins might be needed to obtain the desired cell 
type. Retinoic acid (vitamin A) is an additive required in cell culture 
media for a number of epithelial cell types. Vitamin E and Ascorbate 
(vitamin) are acting as antioxidants. Other antioxidants commonly 
used in serum-free media formulations are β-mercaptoethanol and 
selenium [22]. The importance of the conditioned medium produced 
by stem cells should also be considered in the development of serum-
free media: stem cells in culture may release growth factors thereby 
stimulating their own proliferation and that of nearby cells.
Conclusion
The development of tailored well-defined serum-free media 
provides further advantages in the enrichment of a desired cell type in 
primary cultures therefore producing a more homogeneous outcome 
and preventing potential undesired differentiation of multipotent 
progenitors. On the overall, it is clear that this approach will increase 
clinical efficacy and will provide the highest degree of safety for the 
patient. This is to underline the fact that Quality Assurance is becoming 
increasingly important. Good laboratory practice (GLP) and Good 
Manufacturing Practice (GMP) are now established standards for 
the process development of stem cell therapy products. Good Cell 
Culture Practice (GCCP) is now an attempt to develop a common 
standard for in vitro methods. In this view, the implementation of the 
use of chemically deﬁned, animal component-free media is part of 
the GCCP [23]. In conclusion, as we move to trials based on next-
generation stem cell-based technologies for cardiac regeneration, a 
comprehensive optimization of cell process development is needed 
to ensure optimal efficacy and increased equivalence in the clinical 
setting.
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